164 related articles for article (PubMed ID: 31906724)
21. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
23. [Clinical analysis of 67 patients with brain metastases from breast cancer].
He J; Feng FY; Xing PY; Wang XY; Zhang P
Ai Zheng; 2005 Dec; 24(12):1527-30. PubMed ID: 16351807
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
25. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
[TBL] [Abstract][Full Text] [Related]
26. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
[TBL] [Abstract][Full Text] [Related]
27. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
Dong R; Ji J; Liu H; He X
Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
[TBL] [Abstract][Full Text] [Related]
28. Treatment of brain metastases in patients with HER2+ breast cancer.
Bravo Marques JM
Adv Ther; 2009 Jul; 26 Suppl 1():S18-26. PubMed ID: 19669638
[TBL] [Abstract][Full Text] [Related]
29. Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.
Senda N; Yamaguchi A; Nishimura H; Shiozaki T; Tsuyuki S
Breast Cancer; 2016 Mar; 23(2):323-8. PubMed ID: 26116144
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Bergen ES; Berghoff AS; Rudas M; Preusser M; Bartsch R
Anticancer Drugs; 2015 Jun; 26(5):579-81. PubMed ID: 25714248
[TBL] [Abstract][Full Text] [Related]
31. [A case of local advanced breast cancer with multiple lung metastases successfully treated with multimodal therapy].
Sengoku N; Kuranami M; Handa K; Hayashi K; Enomoto T; Watanabe M
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1927-9. PubMed ID: 15553762
[TBL] [Abstract][Full Text] [Related]
32. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
33. [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Cao KI; Kirova YM
Cancer Radiother; 2014 Jun; 18(3):235-42; quiz 246, 249. PubMed ID: 24731405
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
35. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
[TBL] [Abstract][Full Text] [Related]
36. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
37. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
[TBL] [Abstract][Full Text] [Related]
38. [Remarkable improvement in a patient with metastatic and locally advanced HER2-positive breast cancer treated with trastuzumab plus vinorelbine].
Kanazawa S; Ogata H; Magoshi S; Saito F; Ito T; Kubota Y; Kaneko H
Gan To Kagaku Ryoho; 2012 Mar; 39(3):445-9. PubMed ID: 22421777
[TBL] [Abstract][Full Text] [Related]
39. Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Teplinsky E; Esteva FJ
Curr Oncol Rep; 2015 Oct; 17(10):46. PubMed ID: 26314739
[TBL] [Abstract][Full Text] [Related]
40. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
